The mental healthcare system is in desperate need of innovation.
By combining the ubiquity of digital tools with emerging technologies, we stand to be able to bring patients the care they need, wherever they need it.

An atai Life Sciences company
IntroSpect Digital Therapeutics is an initiative designed to extend the life changing potential of psychedelics-assisted psychotherapy to patients in a scalable and equitable way.
Using the flexibility and power of digital technology allows us to be more capable than ever of meeting patients on their own terms. By using a variety of digital biomarkers, we stand to make treatments increasingly refined, effective, and – most importantly for mental healthcare – individualized.’- David Keene
, CEO, Introspect Digital Therapeutics